Oncology Products with Purpose
Our innovative approach to solving problems in oncology and for orphan indications ensures we bring products to market that ease the burden of use for caregivers and enhance patient outcomes.
We are dedicated to developing novel products that are clinically impactful focusing on the pharmaceutical formulation to ensure high quality, greater dose flexibility, easier administration and better acceptance of medicines.
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our oncology drug SH-105. The FDA’s prompt and definitive response confirms our clinical and regulatory strategy and aligns with our plan to accelerate the filing of our New Drug Application (‘NDA’).
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (FDA) on our third oncology drug SH-110. This proprietary product will have a significant benefit to patients suffering from brain cancer ultimately reducing treatment burden and providing a palatable age appropriate treatment.
The successful GMP manufacture of Shorla’s first sterile oncology product was recently completed via state of the art robotic filling technology in our European GMP accredited partner facility. This important milestone will support the submission of Shorla’s imminent license application to the US FDA.
By combining innovation and compassion, our pipeline contains products that make a difference to patients’ lives. Our product development strategy extends beyond specialty pharma and focuses on the end user, ultimately creating a pipeline with value and purpose.
This is where you place the text describing the work you are doing on this product.